<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954327</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00082571</org_study_id>
    <nct_id>NCT03954327</nct_id>
  </id_info>
  <brief_title>Combination Antiretroviral Therapy (cART) for PBC</brief_title>
  <official_title>Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir
      Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to
      Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at
      unblinding. All patients will be offered an additional 12 months open label therapy.
      Observational, open label study will be performed in parallel using Emtricitabine
      (FTC)/Tenofovir Disoproxil (TDF) &amp; Raltegravir in liver transplant recipients meeting all
      entry criteria except for use of immunosuppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:

      Greater than 10% difference in mean percentage of alkaline phosphatase (ALP) reduction in
      cART vs. placebo at 6 and 12 months.

      Secondary endpoints:

        1. Serum biochemistries bilirubin, aspartate aminotransferase (AST), alanine
           aminotransferase (ALT) and gamma-glutamyltransferase (GGT) will be studied as continuous
           variables.

        2. Composite endpoint used for the POISE study [A Placebo-Controlled Trial of Obeticholic
           Acid in Primary Biliary Cholangitis]: (i) reduction of ALP to &lt; 1.67 upper limit of
           normal, (ii) normalization of bilirubin within upper limit of normal (ULN) and (iii)
           reduction of ALP by &gt; 15% at 6 and 12 months.

        3. Symptomatic evaluation performed using the PBC-40 to assess five symptom domains
           relating to fatigue, itch, cognitive symptoms, social and emotional symptoms, and other
           symptoms.

        4. Histological change in grade and stage of PBC using the Nakanuma scoring system for a
           subgroup of patients undergoing liver biopsy [liver biopsy not compulsory for study].

        5. Serial human betaretrovirus measurement in peripheral blood and cellular immune response
           to viral peptides.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in alkaline phosphatase levels</measure>
    <time_frame>12 months</time_frame>
    <description>Mean changes in alkaline phosphatase levels after 12 months treatment with combination antiretroviral therapy or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial changes in alkaline phosphatase</measure>
    <time_frame>Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]</time_frame>
    <description>Serial changes in alkaline phosphatase levels with combination antiretroviral therapy or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial changes in ALT</measure>
    <time_frame>Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]</time_frame>
    <description>Serial changes in ALT levels with combination antiretroviral therapy or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial changes in bilirubin</measure>
    <time_frame>Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]</time_frame>
    <description>Serial changes in bilirubin levels with combination antiretroviral therapy or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of the composite biochemistry endpoint</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>(i) reduction of ALP to &lt; 1.67 upper limit of normal, (ii) normalization of bilirubin within ULN and (iii) reduction of ALP by &gt; 15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Betaretrovirus load in peripheral blood</measure>
    <time_frame>Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy</time_frame>
    <description>Quantification of Human Betaretrovirus DNA or RNA levels in peripheral blood measured by Quantigene or polymerase chain reaction with therapy or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma release to Human Betaretrovirus peptide stimulation</measure>
    <time_frame>Evaluation at baseline, 6 months and end of RCT; then 6 monthly to end of open label therapy</time_frame>
    <description>Concentration of interferon gamma released from peripheral blood mononuclear cells stimulated by Human Betaretrovirus peptides in vitro in response to treatment or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver histology</measure>
    <time_frame>Pretreatment biopsy and 24 month biopsy after initiation of study therapy</time_frame>
    <description>Liver histology will be measured in a scale for staging and grading disease using the Nakanuma scoring system. Scores for fibrosis, bile duct loss, and chronic cholestasis will be combined for staging: stage 1, total score of 0; stage 2, score 1-3; stage 3, score 4-6; and stage 4, score 7-9. Cholangitis activity and hepatitis activity will be graded as 0-3, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) &amp; Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)</intervention_name>
    <description>Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day</description>
    <arm_group_label>Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) &amp; Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir (RTF) 600 mg two tablets by mouth once per day</description>
    <arm_group_label>Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) &amp; Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule [CEBOCAP]</intervention_name>
    <description>Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 years old of either sex,

          -  Anti-mitochondrial antibody +ve or liver histology compatible with PBC,

          -  stable UDCA dose of 13-15 mg/kg for &gt; 12 months or intolerant to UDCA,

          -  ALP at least 1.67 x ULN or abnormal bilirubin less than 2x ULN

          -  able to read and sign informed consent form.

        Exclusion Criteria:

          -  subjects with baseline total bilirubin &gt; 2 x ULN,

          -  use of non-standard or experimental therapy within the last 6 months,

          -  advanced liver disease: INR &gt; 1.2 ULN, Albumin &lt; 35 g/L lower limit of normal,
             platelets &lt; 120,000, Childs Pugh class B or C cirrhosis, presence of grade 2 varices
             or previous variceal hemorrhage, encephalopathy, ascites or need for liver
             transplantation within the next two years;

          -  secondary diagnosis such as HIV, viral hepatitis, drug induced liver injury,
             extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver -
             regular use of &gt; 30g alcohol/day in the last year;

          -  a predicted survival of less than 3 years from malignant or other life threatening
             disease;

          -  hepatic mass consistent with hepatocellular carcinoma ;

          -  previous allergic reaction to study medications;

          -  Glomerular Filtration Rate less than &lt; 30 mL/min as measured Cockcroft-Gault formula;

          -  pregnancy, breast-feeding or pre-menopausal patients not using contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Mason, MD</last_name>
    <phone>780-492-8172</phone>
    <email>andrew.mason@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Breanne Stewart, RN</last_name>
    <phone>780974-8606</phone>
    <email>breanne1@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew Mason, MD</last_name>
      <phone>780-492-8172</phone>
      <email>andrew.mason@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Breanne Stewart, RN</last_name>
      <phone>780-9748606</phone>
      <email>breanne1@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Aldo Montano Loza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schokrollah Elahi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Yoshida, MD</last_name>
      <email>eric.yoshida@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Vladimir Marquez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hin Hin Ko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Aliya Gulamhusein, MD</last_name>
      <email>Aliya.Gulamhusein@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Vincent, MD</last_name>
      <email>catherine.vincent@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

